Details of the Drug Combination

General Information of Drug Combination (ID: DC1IJG0)

Drug Combination Name

Romidepsin Mitomycin

Indication

Disease Entry	Status	REF
High grade ovarian serous adenocarcinoma	Investigative	[1]

Component Drugs

Romidepsin DMT5GNL

Mitomycin DMH0ZJE

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: OVCAR-5

Zero Interaction Potency (ZIP) Score: 2.8

Bliss Independence Score: 3.38

Loewe Additivity Score: 2.85

LHighest Single Agent (HSA) Score: 6.89

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Romidepsin

Disease Entry	ICD 11	Status	REF
Cutaneous T-cell lymphoma	2B01	Approved	[2]
Gastrin-producing neuroendocrine tumor	N.A.	Approved	[3]
Glucagonoma	N.A.	Approved	[3]
Insulinoma	2C10.1	Approved	[3]
Lung carcinoid tumor	N.A.	Approved	[3]
Melanoma	2C30	Approved	[3]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified	N.A.	Approved	[3]
Primary cutaneous T-cell lymphoma	N.A.	Approved	[3]
Urethral cancer	2C93	Approved	[3]
Peripheral T-cell lymphoma	2A90.C	Phase 3	[4]
Renal cell carcinoma	2C90	Phase 3	[2]

Romidepsin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Histone deacetylase 1 (HDAC1)	TT6R7JZ	HDAC1_HUMAN	Inhibitor	[10]
------------------------------------------------------------------------------------

Romidepsin Interacts with 2 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[11]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[11]
------------------------------------------------------------------------------------

Romidepsin Interacts with 3 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[12]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[13]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Metabolism	[14]
------------------------------------------------------------------------------------

Romidepsin Interacts with 41 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Expression	[15]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Affects Expression	[16]
E3 SUMO-protein ligase CBX4 (CBX4)	OT4XVRRF	CBX4_HUMAN	Increases Expression	[17]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[18]
Bcl-2-like protein 11 (BCL2L11)	OTNQQWFJ	B2L11_HUMAN	Increases Expression	[19]
Growth arrest and DNA damage-inducible protein GADD45 beta (GADD45B)	OTL9I7LO	GA45B_HUMAN	Increases Expression	[20]
Serine/threonine-protein kinase 17B (STK17B)	OT4NYNO8	ST17B_HUMAN	Increases Expression	[17]
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Decreases Expression	[21]
RAF proto-oncogene serine/threonine-protein kinase (RAF1)	OT51LSFO	RAF1_HUMAN	Decreases Expression	[21]
Receptor tyrosine-protein kinase erbB-2 (ERBB2)	OTOAUNCK	ERBB2_HUMAN	Decreases Expression	[21]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Decreases Phosphorylation	[21]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[22]
Clusterin (CLU)	OTQGG0JM	CLUS_HUMAN	Increases Expression	[17]
G2/mitotic-specific cyclin-B1 (CCNB1)	OT19S7E5	CCNB1_HUMAN	Decreases Expression	[21]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Phosphorylation	[9]
Transcription factor JunD (JUND)	OTNKACJD	JUND_HUMAN	Increases Expression	[17]
Nuclear factor NF-kappa-B p105 subunit (NFKB1)	OTNRRD8I	NFKB1_HUMAN	Increases Expression	[22]
Cyclin-A2 (CCNA2)	OTPHHYZJ	CCNA2_HUMAN	Decreases Expression	[21]
NF-kappa-B inhibitor alpha (NFKBIA)	OTFT924M	IKBA_HUMAN	Increases Expression	[22]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Decreases Phosphorylation	[9]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Decreases Phosphorylation	[9]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Increases Phosphorylation	[23]
Receptor-type tyrosine-protein kinase FLT3 (FLT3)	OTMSRYMK	FLT3_HUMAN	Decreases Phosphorylation	[9]
Sterol regulatory element-binding protein 1 (SREBF1)	OTWBRPAI	SRBP1_HUMAN	Increases Expression	[17]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Increases Expression	[24]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[21]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Cleavage	[22]
Friend leukemia integration 1 transcription factor (FLI1)	OT0EV3LX	FLI1_HUMAN	Decreases Expression	[25]
RNA-binding protein EWS (EWSR1)	OT7SRHV3	EWS_HUMAN	Decreases Expression	[25]
DNA repair protein RAD51 homolog 1 (RAD51)	OTNVWGC1	RAD51_HUMAN	Decreases Expression	[9]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	OT2YYI1A	MCL1_HUMAN	Increases Expression	[23]
Bcl-2-interacting killer (BIK)	OTTH1T3D	BIK_HUMAN	Increases Expression	[17]
Spectrin alpha chain, non-erythrocytic 1 (SPTAN1)	OT6VY3A3	SPTN1_HUMAN	Increases Expression	[17]
Nuclear receptor subfamily 1 group I member 3 (NR1I3)	OTS3SGH7	NR1I3_HUMAN	Increases Expression	[26]
Bcl-2 homologous antagonist/killer (BAK1)	OTDP6ILW	BAK_HUMAN	Increases Expression	[23]
Histone H3.1t (H3-4)	OTY6ITYF	H31T_HUMAN	Increases Acetylation	[26]
Sodium/iodide cotransporter (SLC5A5)	OTU7E9G7	SC5A5_HUMAN	Increases Expression	[27]
Mitogen-activated protein kinase kinase kinase 3 (MAP3K3)	OT53LJGW	M3K3_HUMAN	Increases Expression	[17]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Affects Metabolism	[28]
Multidrug resistance-associated protein 1 (ABCC1)	OTGUN89S	MRP1_HUMAN	Decreases Response To Substance	[29]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Decreases Response To Substance	[22]
------------------------------------------------------------------------------------


⏷ Show the Full List of 41 DOT(s)

Indication(s) of Mitomycin

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[5]
Gastrointestinal cancer	2C11	Approved	[5]
Pancreatic adenocarcinoma	N.A.	Approved	[6]
Solid tumour/cancer	2A00-2F9Z	Approved	[7]
Urinary bladder cancer	N.A.	Approved	[6]
Urinary bladder neoplasm	N.A.	Approved	[6]
Urinary system neoplasm	N.A.	Approved	[6]
Urinary tract disease	GC2Z	Approved	[6]
Bladder disease	DC11-DC1Z	Investigative	[6]
Colon cancer	2B90.Z	Investigative	[6]

Mitomycin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Binder	[36]
------------------------------------------------------------------------------------

Mitomycin Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[37]
------------------------------------------------------------------------------------

Mitomycin Interacts with 274 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Expression	[38]
Alternative prion protein (PRNP)	OTE85L1Q	APRIO_HUMAN	Increases Expression	[39]
Amyloid-beta precursor protein (APP)	OTKFD7R4	A4_HUMAN	Increases Expression	[39]
HLA class I histocompatibility antigen, C alpha chain (HLA-C)	OTV38BUJ	HLAC_HUMAN	Decreases Expression	[39]
Bone morphogenetic protein 4 (BMP4)	OTPZMDFH	BMP4_HUMAN	Decreases Expression	[39]
G2/mitotic-specific cyclin-B1 (CCNB1)	OT19S7E5	CCNB1_HUMAN	Increases Expression	[39]
Early growth response protein 1 (EGR1)	OTCP6XGZ	EGR1_HUMAN	Increases Expression	[39]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4)	OTRFV19J	ATF4_HUMAN	Increases Expression	[39]
DNA ligase 1 (LIG1)	OTEEQS43	DNLI1_HUMAN	Decreases Expression	[39]
Nuclear transcription factor Y subunit alpha (NFYA)	OTWFFOVH	NFYA_HUMAN	Increases Expression	[39]
Ephrin type-A receptor 2 (EPHA2)	OTI6QNX2	EPHA2_HUMAN	Decreases Expression	[39]
Replication factor C subunit 4 (RFC4)	OTWALD2R	RFC4_HUMAN	Decreases Expression	[39]
Matrix metalloproteinase-14 (MMP14)	OT9C197Z	MMP14_HUMAN	Decreases Expression	[39]
Activated RNA polymerase II transcriptional coactivator p15 (SUB1)	OTK71JYU	TCP4_HUMAN	Increases Expression	[39]
Small ribosomal subunit protein eS1 (RPS3A)	OTUEP7CL	RS3A_HUMAN	Increases Expression	[39]
Microtubule-associated protein RP/EB family member 1 (MAPRE1)	OTCVQD60	MARE1_HUMAN	Increases Expression	[39]
Histone-binding protein RBBP7 (RBBP7)	OTLB56HX	RBBP7_HUMAN	Increases Expression	[39]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Increases Expression	[40]
TP53-regulated inhibitor of apoptosis 1 (TRIAP1)	OTEAUJXN	TRIA1_HUMAN	Increases Expression	[41]
Superoxide dismutase (SOD1)	OT39TA1L	SODC_HUMAN	Increases Expression	[41]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Expression	[41]
Heat shock cognate 71 kDa protein (HSPA8)	OTJI2RCI	HSP7C_HUMAN	Increases Expression	[41]
Proliferating cell nuclear antigen (PCNA)	OTHZ1RIA	PCNA_HUMAN	Increases Expression	[41]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)	OTDRV63V	GA45A_HUMAN	Increases Expression	[41]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Increases Expression	[41]
Quinone oxidoreductase PIG3 (TP53I3)	OTSCM68G	QORX_HUMAN	Increases Expression	[41]
DNA damage-binding protein 2 (DDB2)	OTO8HVVB	DDB2_HUMAN	Increases Expression	[41]
Cystine/glutamate transporter (SLC7A11)	OTKJ6PXW	XCT_HUMAN	Decreases Expression	[42]
Succinate dehydrogenase assembly factor 1, mitochondrial (SDHAF1)	OTDG5VW7	SDHF1_HUMAN	Decreases Expression	[31]
Serine/threonine-protein kinase Sgk1 (SGK1)	OT301T1U	SGK1_HUMAN	Decreases Expression	[31]
E3 ubiquitin-protein ligase TRIM38 (TRIM38)	OT6SP1M9	TRI38_HUMAN	Decreases Expression	[31]
Torsin-1A (TOR1A)	OTYCLGJU	TOR1A_HUMAN	Decreases Expression	[31]
Telomerase reverse transcriptase (TERT)	OT085VVA	TERT_HUMAN	Decreases Expression	[43]
Serine/threonine-protein kinase Chk1 (CHEK1)	OTTTI622	CHK1_HUMAN	Increases Phosphorylation	[44]
Transcription factor EC (TFEC)	OTUST8MR	TFEC_HUMAN	Decreases Expression	[31]
Regulator of G-protein signaling 16 (RGS16)	OTBKZASI	RGS16_HUMAN	Decreases Expression	[31]
E3 ubiquitin-protein ligase RNF113A (RNF113A)	OTR6N7HU	R113A_HUMAN	Decreases Expression	[31]
HMG box-containing protein 1 (HBP1)	OTDPGGDV	HBP1_HUMAN	Decreases Expression	[31]
Kinesin-like protein KIF20A (KIF20A)	OTXOQHE0	KI20A_HUMAN	Decreases Expression	[31]
Myelin protein zero-like protein 1 (MPZL1)	OTJSUUHR	MPZL1_HUMAN	Decreases Expression	[31]
Serine/threonine-protein kinase Chk2 (CHEK2)	OT8ZPCNS	CHK2_HUMAN	Increases Phosphorylation	[44]
Transforming growth factor beta-1 proprotein (TGFB1)	OTV5XHVH	TGFB1_HUMAN	Increases Expression	[45]
Interleukin-1 alpha (IL1A)	OTPSGILV	IL1A_HUMAN	Increases Expression	[46]
Thymidine kinase, cytosolic (TK1)	OTY5JFM1	KITH_HUMAN	Increases Mutagenesis	[47]
Plasminogen activator inhibitor 1 (SERPINE1)	OTT0MPQ3	PAI1_HUMAN	Increases Expression	[46]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Increases Expression	[46]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Decreases Expression	[48]
Fibroblast growth factor 2 (FGF2)	OT7YUJ9F	FGF2_HUMAN	Increases Expression	[45]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Activity	[49]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Increases Expression	[50]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Increases Expression	[51]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Increases Expression	[50]
CD59 glycoprotein (CD59)	OTSUMQDH	CD59_HUMAN	Increases Mutagenesis	[52]
Histone H2AX (H2AX)	OT18UX57	H2AX_HUMAN	Increases Expression	[53]
Beta-galactosidase (GLB1)	OTB0TKAG	BGAL_HUMAN	Increases Activity	[46]
rRNA 2'-O-methyltransferase fibrillarin (FBL)	OTRODIE5	FBRL_HUMAN	Affects Localization	[54]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2)	OTIN6G20	CPT2_HUMAN	Decreases Expression	[31]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Increases Expression	[55]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Increases Phosphorylation	[56]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Increases Phosphorylation	[56]
GTP cyclohydrolase 1 (GCH1)	OTOZ6NSL	GCH1_HUMAN	Decreases Expression	[31]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Expression	[57]
Replication factor C subunit 1 (RFC1)	OT3L5PK3	RFC1_HUMAN	Decreases Expression	[31]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[58]
RNA-binding protein 34 (RBM34)	OTX3LUGI	RBM34_HUMAN	Decreases Expression	[31]
Tumor necrosis factor ligand superfamily member 6 (FASLG)	OTZARCHH	TNFL6_HUMAN	Increases Expression	[55]
Glycogen synthase kinase-3 beta (GSK3B)	OTL3L14B	GSK3B_HUMAN	Increases Phosphorylation	[46]
LIM/homeobox protein Lhx2 (LHX2)	OTK61NP8	LHX2_HUMAN	Decreases Expression	[31]
DNA mismatch repair protein Msh6 (MSH6)	OT46FP09	MSH6_HUMAN	Decreases Expression	[31]
RecQ-like DNA helicase BLM (BLM)	OTEJOAJX	BLM_HUMAN	Decreases Expression	[31]
Ataxin-1 (ATXN1)	OTQF0HNR	ATX1_HUMAN	Decreases Expression	[31]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Activity	[57]
Ras-related protein Rap-2b (RAP2B)	OTD2NDQP	RAP2B_HUMAN	Decreases Expression	[31]
Cytochrome c (CYCS)	OTBFALJD	CYC_HUMAN	Increases Secretion	[58]
E3 ubiquitin-protein ligase Mdm2 (MDM2)	OTOVXARF	MDM2_HUMAN	Increases Expression	[59]
Transcription factor E2F1 (E2F1)	OTLKYBBC	E2F1_HUMAN	Decreases Expression	[31]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Increases Expression	[60]
Protein kinase C zeta type (PRKCZ)	OTN2FE42	KPCZ_HUMAN	Increases Cleavage	[58]
DNA repair protein RAD51 homolog 1 (RAD51)	OTNVWGC1	RAD51_HUMAN	Increases Expression	[56]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Decreases Expression	[51]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Decreases Expression	[61]
Tripartite motif-containing protein 26 (TRIM26)	OTS0DJIP	TRI26_HUMAN	Decreases Expression	[31]
E3 ubiquitin-protein ligase TRIM32 (TRIM32)	OTJOV0PG	TRI32_HUMAN	Decreases Expression	[31]
Chromatin assembly factor 1 subunit A (CHAF1A)	OTXSSY4H	CAF1A_HUMAN	Decreases Expression	[31]
Chromatin assembly factor 1 subunit B (CHAF1B)	OTOMK4KH	CAF1B_HUMAN	Decreases Expression	[31]
Interleukin-18 (IL18)	OTBB2A8O	IL18_HUMAN	Decreases Expression	[60]
Protein BTG3 (BTG3)	OT9ANHVT	BTG3_HUMAN	Decreases Expression	[31]
Histone RNA hairpin-binding protein (SLBP)	OTVYYQRT	SLBP_HUMAN	Decreases Expression	[31]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Activity	[58]
Transforming growth factor-beta-induced protein ig-h3 (TGFBI)	OTR443C5	BGH3_HUMAN	Decreases Expression	[61]
Neutral amino acid transporter B(0) (SLC1A5)	OTE2H26Q	AAAT_HUMAN	Decreases Expression	[31]
Protein MCM10 homolog (MCM10)	OTV0O3JN	MCM10_HUMAN	Decreases Expression	[31]
Partner and localizer of BRCA2 (PALB2)	OT6DNDBG	PALB2_HUMAN	Decreases Expression	[31]
Leucine-rich repeat-containing protein 47 (LRRC47)	OTSE8NAO	LRC47_HUMAN	Decreases Expression	[31]
Bcl2-associated agonist of cell death (BAD)	OT63ERYM	BAD_HUMAN	Increases Expression	[57]
Cytochrome c oxidase assembly factor 7 (COA7)	OTRQJYL6	COA7_HUMAN	Decreases Expression	[31]
Mitochondrial potassium channel (CCDC51)	OTOJNHNA	MITOK_HUMAN	Decreases Expression	[31]
Integrator complex subunit 15 (INTS15)	OT3O4INM	INT15_HUMAN	Decreases Expression	[31]
Krueppel-like factor 6 (KLF6)	OTQY9S7F	KLF6_HUMAN	Decreases Expression	[31]
Cell division control protein 6 homolog (CDC6)	OTX93FE7	CDC6_HUMAN	Decreases Expression	[31]
Growth/differentiation factor 15 (GDF15)	OTWQN50N	GDF15_HUMAN	Increases Expression	[31]
Protein orai-3 (ORAI3)	OTUP3OH3	ORAI3_HUMAN	Decreases Expression	[31]
Protein pelota homolog (PELO)	OTF3WLIM	PELO_HUMAN	Decreases Expression	[31]
TIMELESS-interacting protein (TIPIN)	OT9PZHXV	TIPIN_HUMAN	Decreases Expression	[31]
Fanconi anemia group D2 protein (FANCD2)	OTVEB5LF	FACD2_HUMAN	Increases Ubiquitination	[44]
tRNA pseudouridine(38/39) synthase (PUS3)	OT6WG6M2	PUS3_HUMAN	Decreases Expression	[31]
Transmembrane protein 185B (TMEM185B)	OTGNYS0J	T185B_HUMAN	Decreases Expression	[31]
Interferon-stimulated 20 kDa exonuclease-like 2 (ISG20L2)	OT3Q11WQ	I20L2_HUMAN	Decreases Expression	[31]
GrpE protein homolog 1, mitochondrial (GRPEL1)	OT8O00YJ	GRPE1_HUMAN	Decreases Expression	[31]
Forkhead box protein J2 (FOXJ2)	OTPT639J	FOXJ2_HUMAN	Decreases Expression	[31]
Homologous-pairing protein 2 homolog (PSMC3IP)	OT9UB5UO	HOP2_HUMAN	Decreases Expression	[31]
rRNA methyltransferase 2, mitochondrial (MRM2)	OTRYA1HU	MRM2_HUMAN	Decreases Expression	[31]
Frizzled-1 (FZD1)	OTZATHVS	FZD1_HUMAN	Decreases Expression	[31]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Affects Response To Substance	[34]
Tripartite motif-containing protein 2 (TRIM2)	OT0V1YVC	TRIM2_HUMAN	Affects Response To Substance	[34]
Acid ceramidase (ASAH1)	OT1DNGXL	ASAH1_HUMAN	Affects Response To Substance	[34]
Fanconi-associated nuclease 1 (FAN1)	OT1LM1HZ	FAN1_HUMAN	Increases Response To Substance	[62]
Replication factor C subunit 3 (RFC3)	OT1MS7AO	RFC3_HUMAN	Affects Response To Substance	[34]
CD9 antigen (CD9)	OT2184XU	CD9_HUMAN	Affects Response To Substance	[34]
KN motif and ankyrin repeat domain-containing protein 1 (KANK1)	OT2E7A6W	KANK1_HUMAN	Affects Response To Substance	[34]
Aldehyde oxidase (AOX1)	OT2FZP6H	AOXA_HUMAN	Affects Response To Substance	[34]
Mitochondrial fission 1 protein (FIS1)	OT2HL10J	FIS1_HUMAN	Affects Response To Substance	[34]
Cytoplasmic aconitate hydratase (ACO1)	OT2VUR7L	ACOHC_HUMAN	Affects Response To Substance	[34]
Syncytin-2 (ERVFRD-1)	OT3064D7	SYCY2_HUMAN	Affects Response To Substance	[34]
Protein FAM171A1 (FAM171A1)	OT33BHEP	F1711_HUMAN	Affects Response To Substance	[34]
Sister chromatid cohesion protein PDS5 homolog A (PDS5A)	OT34P56Z	PDS5A_HUMAN	Affects Response To Substance	[34]
Excitatory amino acid transporter 3 (SLC1A1)	OT3B9M6W	EAA3_HUMAN	Affects Response To Substance	[34]
Syntabulin (SYBU)	OT3FQV7N	SYBU_HUMAN	Affects Response To Substance	[34]
Fatty acid CoA ligase Acsl3 (ACSL3)	OT3MWER1	ACSL3_HUMAN	Affects Response To Substance	[34]
Prelamin-A/C (LMNA)	OT3SG7ZR	LMNA_HUMAN	Affects Response To Substance	[34]
Methylated-DNA--protein-cysteine methyltransferase (MGMT)	OT40A9WH	MGMT_HUMAN	Increases Response To Substance	[63]
Pyridoxal kinase (PDXK)	OT40AJ5J	PDXK_HUMAN	Affects Response To Substance	[34]
Proteinase-activated receptor 1 (F2R)	OT4WVWBO	PAR1_HUMAN	Affects Response To Substance	[34]
Diamine acetyltransferase 1 (SAT1)	OT52AU22	SAT1_HUMAN	Affects Response To Substance	[34]
Breast cancer type 1 susceptibility protein (BRCA1)	OT5BN6VH	BRCA1_HUMAN	Increases Response To Substance	[64]
Neprilysin (MME)	OT5Q39P8	NEP_HUMAN	Affects Response To Substance	[34]
Lymphokine-activated killer T-cell-originated protein kinase (PBK)	OT5Z27TW	TOPK_HUMAN	Affects Response To Substance	[34]
Protein-glutamine gamma-glutamyltransferase 2 (TGM2)	OT6MFOWF	TGM2_HUMAN	Affects Response To Substance	[34]
G-protein-signaling modulator 2 (GPSM2)	OT6RPMRM	GPSM2_HUMAN	Affects Response To Substance	[34]
Dual specificity protein phosphatase 4 (DUSP4)	OT6WAO12	DUS4_HUMAN	Affects Response To Substance	[34]
Interferon-induced GTP-binding protein Mx1 (MX1)	OT6X8G5T	MX1_HUMAN	Increases Response To Substance	[65]
Plasminogen activator inhibitor 2 (SERPINB2)	OT72QLZB	PAI2_HUMAN	Affects Response To Substance	[34]
Transcriptional regulator ATRX (ATRX)	OT77RSQW	ATRX_HUMAN	Affects Response To Substance	[34]
Monocarboxylate transporter 7 (SLC16A6)	OT7BIIZX	MOT7_HUMAN	Affects Response To Substance	[34]
Ras-related protein Rab-17 (RAB17)	OT7NBUGQ	RAB17_HUMAN	Affects Response To Substance	[34]
Stanniocalcin-2 (STC2)	OT86YP8G	STC2_HUMAN	Affects Response To Substance	[34]
Pirin (PIR)	OT8ALXHU	PIR_HUMAN	Affects Response To Substance	[34]
Myelin proteolipid protein (PLP1)	OT8CM9CX	MYPR_HUMAN	Affects Response To Substance	[34]
Protein-S-isoprenylcysteine O-methyltransferase (ICMT)	OT8CNKBO	ICMT_HUMAN	Affects Response To Substance	[34]
G0/G1 switch protein 2 (G0S2)	OT8FL49L	G0S2_HUMAN	Affects Response To Substance	[34]
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform (PPP2R5E)	OT8GPFT5	2A5E_HUMAN	Decreases Response To Substance	[66]
cAMP-dependent protein kinase inhibitor alpha (PKIA)	OT8M5GVO	IPKA_HUMAN	Affects Response To Substance	[34]
Melanoma-associated antigen 12 (MAGEA12)	OT8ULELL	MAGAC_HUMAN	Affects Response To Substance	[34]
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform (PPP2R2A)	OT9297OG	2ABA_HUMAN	Decreases Response To Substance	[66]
Tissue factor pathway inhibitor (TFPI)	OTA0FX16	TFPI1_HUMAN	Affects Response To Substance	[34]
Acyl-coenzyme A thioesterase 2, mitochondrial (ACOT2)	OTAKUO27	ACOT2_HUMAN	Affects Response To Substance	[34]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1)	OTAYZZE6	AL3A1_HUMAN	Affects Response To Substance	[67]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1)	OTB06ESI	ACSL1_HUMAN	Affects Response To Substance	[34]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Affects Response To Substance	[34]
Cochlin (COCH)	OTBEHD89	COCH_HUMAN	Affects Response To Substance	[34]
ETS domain-containing protein Elk-3 (ELK3)	OTBM9BHT	ELK3_HUMAN	Affects Response To Substance	[34]
High mobility group protein HMGI-C (HMGA2)	OTBMBHHL	HMGA2_HUMAN	Affects Response To Substance	[34]
Protein PRRC2C (PRRC2C)	OTBX3MXM	PRC2C_HUMAN	Affects Response To Substance	[34]
Melanocyte protein PMEL (PMEL)	OTCDDHHM	PMEL_HUMAN	Affects Response To Substance	[34]
BMP and activin membrane-bound inhibitor homolog (BAMBI)	OTCEJ8W5	BAMBI_HUMAN	Affects Response To Substance	[34]
Creatine kinase U-type, mitochondrial (CKMT1A)	OTCINHH5	KCRU_HUMAN	Affects Response To Substance	[34]
Sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1)	OTCJ458Q	AT1A1_HUMAN	Affects Response To Substance	[34]
CD166 antigen (ALCAM)	OTCO4LP7	CD166_HUMAN	Affects Response To Substance	[34]
Cytochrome c oxidase copper chaperone (COX17)	OTCP4LH2	COX17_HUMAN	Affects Response To Substance	[34]
Interleukin-6 receptor subunit alpha (IL6R)	OTCQL07Z	IL6RA_HUMAN	Decreases Response To Substance	[68]
Collagen alpha-3(IX) chain (COL9A3)	OTCUJOEK	CO9A3_HUMAN	Affects Response To Substance	[34]
A-kinase anchor protein 12 (AKAP12)	OTCVRDDX	AKA12_HUMAN	Affects Response To Substance	[34]
Dystrophin (DMD)	OTD21T5J	DMD_HUMAN	Affects Response To Substance	[34]
Dickkopf-related protein 3 (DKK3)	OTDU94EY	DKK3_HUMAN	Affects Response To Substance	[34]
dTDP-D-glucose 4,6-dehydratase (TGDS)	OTEOFLOS	TGDS_HUMAN	Affects Response To Substance	[34]
Calmegin (CLGN)	OTEWVFQV	CLGN_HUMAN	Affects Response To Substance	[34]
Ras association domain-containing protein 1 (RASSF1)	OTEZIPB7	RASF1_HUMAN	Increases Response To Substance	[69]
Protocadherin Fat 1 (FAT1)	OTF174DH	FAT1_HUMAN	Affects Response To Substance	[34]
Midkine (MDK)	OTF24HKC	MK_HUMAN	Affects Response To Substance	[34]
Serine/arginine-rich splicing factor 1 (SRSF1)	OTF61HOV	SRSF1_HUMAN	Affects Response To Substance	[34]
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform (PPP2R5C)	OTF7CGO2	2A5G_HUMAN	Increases Response To Substance	[66]
G antigen 7 (GAGE7)	OTF8BTR9	GAGE7_HUMAN	Affects Response To Substance	[34]
Serglycin (SRGN)	OTFAVSX0	SRGN_HUMAN	Affects Response To Substance	[34]
Catenin alpha-1 (CTNNA1)	OTFC725Z	CTNA1_HUMAN	Affects Response To Substance	[34]
Sortilin (SORT1)	OTFCQ4B1	SORT_HUMAN	Affects Response To Substance	[34]
Baculoviral IAP repeat-containing protein 2 (BIRC2)	OTFXFREP	BIRC2_HUMAN	Affects Response To Substance	[34]
Myelin basic protein (MBP)	OTFZCEDB	MBP_HUMAN	Affects Response To Substance	[34]
Tudor domain-containing protein 3 (TDRD3)	OTG83E2C	TDRD3_HUMAN	Affects Response To Substance	[34]
Enhancer of filamentation 1 (NEDD9)	OTGCFN4M	CASL_HUMAN	Affects Response To Substance	[34]
Squalene synthase (FDFT1)	OTGDISIT	FDFT_HUMAN	Affects Response To Substance	[34]
Multidrug resistance-associated protein 1 (ABCC1)	OTGUN89S	MRP1_HUMAN	Decreases Response To Substance	[70]
Sigma intracellular receptor 2 (TMEM97)	OTH76ZWK	SGMR2_HUMAN	Affects Response To Substance	[34]
Transmembrane protein 156 (TMEM156)	OTH7YJID	TM156_HUMAN	Affects Response To Substance	[34]
Probable JmjC domain-containing histone demethylation protein 2C (JMJD1C)	OTHAWK8C	JHD2C_HUMAN	Affects Response To Substance	[34]
Unconventional myosin-X (MYO10)	OTHB78ZQ	MYO10_HUMAN	Affects Response To Substance	[34]
Tribbles homolog 2 (TRIB2)	OTHSX3MX	TRIB2_HUMAN	Affects Response To Substance	[34]
Actin-binding LIM protein 1 (ABLIM1)	OTHXEK3E	ABLM1_HUMAN	Affects Response To Substance	[34]
DNA damage-inducible transcript 4 protein (DDIT4)	OTHY8SY4	DDIT4_HUMAN	Affects Response To Substance	[34]
Protein S100-A11 (S100A11)	OTI57KDN	S10AB_HUMAN	Affects Response To Substance	[34]
Protein S100-A10 (S100A10)	OTI71243	S10AA_HUMAN	Affects Response To Substance	[34]
Melanoma-associated antigen 6 (MAGEA6)	OTI8S0O2	MAGA6_HUMAN	Affects Response To Substance	[34]
Runt-related transcription factor 3 (RUNX3)	OTITK1XD	RUNX3_HUMAN	Increases Response To Substance	[71]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Affects Response To Substance	[34]
Nuclear receptor-interacting protein 1 (NRIP1)	OTIZOJQV	NRIP1_HUMAN	Affects Response To Substance	[34]
Protein c-Fos (FOS)	OTJBUVWS	FOS_HUMAN	Affects Response To Substance	[34]
Trefoil factor 3 (TFF3)	OTJJDRTU	TFF3_HUMAN	Affects Response To Substance	[34]
Collagen alpha-2(IV) chain (COL4A2)	OTJK1LKN	CO4A2_HUMAN	Affects Response To Substance	[34]
Hairy/enhancer-of-split related with YRPW motif protein 1 (HEY1)	OTJQL0I3	HEY1_HUMAN	Affects Response To Substance	[34]
E3 ubiquitin-protein ligase MYLIP (MYLIP)	OTL0PFGV	MYLIP_HUMAN	Affects Response To Substance	[34]
Hematopoietically-expressed homeobox protein HHEX (HHEX)	OTLIUVYX	HHEX_HUMAN	Affects Response To Substance	[34]
Glycylpeptide N-tetradecanoyltransferase 2 (NMT2)	OTLNA39Z	NMT2_HUMAN	Affects Response To Substance	[34]
Glutathione S-transferase P (GSTP1)	OTLP0A0Y	GSTP1_HUMAN	Increases Response To Substance	[72]
Protein S100-A4 (S100A4)	OTLRGFSQ	S10A4_HUMAN	Affects Response To Substance	[34]
Tyrosine-protein kinase Fyn (FYN)	OTLSLVZS	FYN_HUMAN	Affects Response To Substance	[34]
Bridging integrator 3 (BIN3)	OTMIWWDW	BIN3_HUMAN	Affects Response To Substance	[34]
Transcription factor AP-2-alpha (TFAP2A)	OTMYT3NK	AP2A_HUMAN	Affects Response To Substance	[34]
Four and a half LIM domains protein 1 (FHL1)	OTN535SU	FHL1_HUMAN	Affects Response To Substance	[34]
Cysteine-rich hydrophobic domain-containing protein 2 (CHIC2)	OTNE3T6Z	CHIC2_HUMAN	Affects Response To Substance	[34]
Inositol monophosphatase 2 (IMPA2)	OTNFB9YN	IMPA2_HUMAN	Affects Response To Substance	[34]
Neural cell adhesion molecule L1 (L1CAM)	OTNWAQ4Y	L1CAM_HUMAN	Affects Response To Substance	[34]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Affects Response To Substance	[73]
Kynurenine--oxoglutarate transaminase 3 (KYAT3)	OTO4U2QK	KAT3_HUMAN	Affects Response To Substance	[34]
Beta-secretase 2 (BACE2)	OTO5YQVK	BACE2_HUMAN	Affects Response To Substance	[34]
Histone deacetylase 9 (HDAC9)	OTO8O0LF	HDAC9_HUMAN	Affects Response To Substance	[34]
SH3 domain-binding protein 5 (SH3BP5)	OTOOEGUJ	3BP5_HUMAN	Affects Response To Substance	[34]
Glutathione S-transferase Mu 4 (GSTM4)	OTOTF8DU	GSTM4_HUMAN	Affects Response To Substance	[34]
Ras-related protein Rab-20 (RAB20)	OTP9OOVS	RAB20_HUMAN	Affects Response To Substance	[34]
Tumor protein D52 (TPD52)	OTPKSK43	TPD52_HUMAN	Affects Response To Substance	[34]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C)	OTPL0AI1	ABC3C_HUMAN	Affects Response To Substance	[34]
Kazrin (KAZN)	OTPM7BYM	KAZRN_HUMAN	Affects Response To Substance	[34]
DNA-binding protein inhibitor ID-4 (ID4)	OTPMJ39I	ID4_HUMAN	Affects Response To Substance	[34]
Centrosomal protein of 57 kDa (CEP57)	OTPOHLIX	CEP57_HUMAN	Affects Response To Substance	[34]
Epithelial membrane protein 2 (EMP2)	OTPS2H0L	EMP2_HUMAN	Affects Response To Substance	[34]
Dermatan-sulfate epimerase (DSE)	OTQ108VJ	DSE_HUMAN	Affects Response To Substance	[34]
Adhesion G-protein coupled receptor G1 (ADGRG1)	OTQBB8NT	AGRG1_HUMAN	Affects Response To Substance	[34]
Cyclic GMP-AMP phosphodiesterase SMPDL3A (SMPDL3A)	OTQDYH8E	ASM3A_HUMAN	Affects Response To Substance	[34]
MAPK/MAK/MRK overlapping kinase (MOK)	OTQK7M9V	MOK_HUMAN	Affects Response To Substance	[34]
High mobility group protein HMG-I/HMG-Y (HMGA1)	OTQUSHPX	HMGA1_HUMAN	Affects Response To Substance	[34]
Receptor tyrosine-protein kinase erbB-3 (ERBB3)	OTRSST0A	ERBB3_HUMAN	Affects Response To Substance	[34]
Dr1-associated corepressor (DRAP1)	OTRWLF6D	NC2A_HUMAN	Affects Response To Substance	[34]
Latent-transforming growth factor beta-binding protein 2 (LTBP2)	OTS88GSD	LTBP2_HUMAN	Affects Response To Substance	[34]
Terminal nucleotidyltransferase 5A (TENT5A)	OTSYF511	TET5A_HUMAN	Affects Response To Substance	[34]
Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF)	OTT5JX1F	LITAF_HUMAN	Affects Response To Substance	[34]
DNA repair protein RAD51 homolog 3 (RAD51C)	OTUD6SY5	RA51C_HUMAN	Increases Response To Substance	[74]
Calcium-dependent secretion activator 2 (CADPS2)	OTV1FW0M	CAPS2_HUMAN	Affects Response To Substance	[34]
Matrilin-2 (MATN2)	OTVDR68G	MATN2_HUMAN	Affects Response To Substance	[34]
NADPH--cytochrome P450 reductase (POR)	OTVIDOCH	NCPR_HUMAN	Increases Response To Substance	[72]
Ensconsin (MAP7)	OTVSSJ33	MAP7_HUMAN	Affects Response To Substance	[34]
Protein artemis (DCLRE1C)	OTW3KB1I	DCR1C_HUMAN	Decreases Response To Substance	[35]
Sorbin and SH3 domain-containing protein 1 (SORBS1)	OTWH8762	SRBS1_HUMAN	Affects Response To Substance	[34]
Protein mago nashi homolog (MAGOH)	OTWRYTOX	MGN_HUMAN	Affects Response To Substance	[34]
Urokinase-type plasminogen activator (PLAU)	OTX0QGKK	UROK_HUMAN	Affects Response To Substance	[34]
Acylamino-acid-releasing enzyme (APEH)	OTX258QE	ACPH_HUMAN	Affects Response To Substance	[34]
Hematopoietic lineage cell-specific protein (HCLS1)	OTX7WGYN	HCLS1_HUMAN	Affects Response To Substance	[34]
S-adenosylhomocysteine hydrolase-like protein 1 (AHCYL1)	OTX8L3M5	SAHH2_HUMAN	Affects Response To Substance	[34]
Long-chain fatty acid transport protein 3 (SLC27A3)	OTXB60L7	S27A3_HUMAN	Affects Response To Substance	[34]
Metallothionein-1E (MT1E)	OTXJKU4Y	MT1E_HUMAN	Affects Response To Substance	[34]
Arginine vasopressin-induced protein 1 (AVPI1)	OTXSBR60	AVPI1_HUMAN	Affects Response To Substance	[34]
Neuroendocrine protein 7B2 (SCG5)	OTXSJMT1	7B2_HUMAN	Affects Response To Substance	[34]
Carbamoyl-phosphate synthase , mitochondrial (CPS1)	OTXV8NSR	CPSM_HUMAN	Affects Response To Substance	[34]
Peripheral myelin protein 22 (PMP22)	OTXWYWCZ	PMP22_HUMAN	Affects Response To Substance	[34]
Kinesin-like protein KIF23 (KIF23)	OTY850JC	KIF23_HUMAN	Affects Response To Substance	[34]
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related (HMG20B)	OTY94WRA	HM20B_HUMAN	Affects Response To Substance	[34]
Protein Niban 1 (NIBAN1)	OTYOLI12	NIBA1_HUMAN	Affects Response To Substance	[34]
LIM and calponin homology domains-containing protein 1 (LIMCH1)	OTYPC4XA	LIMC1_HUMAN	Affects Response To Substance	[34]
Galectin-3 (LGALS3)	OTYQT0ZI	LEG3_HUMAN	Affects Response To Substance	[34]
L-dopachrome tautomerase (DCT)	OTYVNTBG	TYRP2_HUMAN	Affects Response To Substance	[34]
Epithelial discoidin domain-containing receptor 1 (DDR1)	OTYW1SH8	DDR1_HUMAN	Affects Response To Substance	[34]
Tissue factor pathway inhibitor 2 (TFPI2)	OTZCRWOR	TFPI2_HUMAN	Affects Response To Substance	[34]
Suppressor of tumorigenicity 7 protein (ST7)	OTZG8RC6	ST7_HUMAN	Affects Response To Substance	[34]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Increases Response To Substance	[72]
CTD small phosphatase-like protein (CTDSPL)	OTZJ0CZK	CTDSL_HUMAN	Affects Response To Substance	[34]
C-X-C motif chemokine 5 (CXCL5)	OTZOUPCA	CXCL5_HUMAN	Affects Response To Substance	[34]
Eukaryotic translation initiation factor 5B (EIF5B)	OTZTT22W	IF2P_HUMAN	Affects Response To Substance	[34]
------------------------------------------------------------------------------------


⏷ Show the Full List of 274 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Clear cell renal cell carcinoma	DCXZJL2	786-0	Investigative	[75]
Diffuse large B cell lymphoma	DCGKD24	TMD8	Investigative	[75]
Ewing sarcoma	DCFQFM2	TC-71	Investigative	[75]
Glioblastoma	DCX9IQN	SNB-75	Investigative	[75]
Breast adenocarcinoma	DCEZNO8	MDA-MB-468	Investigative	[76]
Adenocarcinoma	DCD2NAR	DU-145	Investigative	[1]
Adenocarcinoma	DCFC41L	OVCAR3	Investigative	[1]
Adenocarcinoma	DC4C24I	NCIH23	Investigative	[1]
Adenocarcinoma	DC446C3	HT29	Investigative	[1]
Adenocarcinoma	DCYAYSK	HCC-2998	Investigative	[1]
Amelanotic melanoma	DCPR5MR	M14	Investigative	[1]
High grade ovarian serous adenocarcinoma	DC1JJUQ	OVCAR-8	Investigative	[1]
Lung adenocarcinoma	DC2OJG5	HOP-62	Investigative	[1]
Malignant melanoma	DCGMVHT	LOX IMVI	Investigative	[1]
Malignant melanoma	DCB78ED	UACC62	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 15 DrugCom(s)

References

1	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7006).
3	Romidepsin FDA Label
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7089).
6	Mitomycin FDA Label
7	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
8	Inhibition of transcription, expression, and secretion of the vascular epithelial growth factor in human epithelial endometriotic cells by romidepsin. Fertil Steril. 2011 Apr;95(5):1579-83. doi: 10.1016/j.fertnstert.2010.12.058. Epub 2011 Feb 4.
9	Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. Arch Toxicol. 2022 Jan;96(1):177-193. doi: 10.1007/s00204-021-03174-1. Epub 2021 Oct 19.
10	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
11	Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
12	A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011 May;13(5):509-16.
13	Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
14	FDA Label of Romidepsin. The 2020 official website of the U.S. Food and Drug Administration.
15	Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J Pharmacol Exp Ther. 2005 Jul;314(1):467-75. doi: 10.1124/jpet.105.083956. Epub 2005 Apr 15.
16	Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell Biol. 2006 Nov;26(22):8572-85.
17	5-Aza-2'-deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer). Biochem Biophys Res Commun. 2006 Dec 15;351(2):455-61. doi: 10.1016/j.bbrc.2006.10.055. Epub 2006 Oct 18.
18	Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 2006 Jul 15;66(14):7317-25. doi: 10.1158/0008-5472.CAN-06-0680.
19	Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int J Cancer. 2004 Jun 10;110(2):301-8. doi: 10.1002/ijc.20117.
20	A sequential treatment of depsipeptide followed by 5-azacytidine enhances Gadd45beta expression in hepatocellular carcinoma cells. Anticancer Res. 2007 Nov-Dec;27(6B):3783-9.
21	Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res. 2004 Mar 1;10(5):1813-25. doi: 10.1158/1078-0432.ccr-0901-3.
22	Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res. 2008 Jan 15;14(2):549-58. doi: 10.1158/1078-0432.CCR-07-1934.
23	Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. Oncotarget. 2016 Oct 25;7(43):69804-69815. doi: 10.18632/oncotarget.12001.
24	Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood. 2006 Feb 15;107(4):1546-54. doi: 10.1182/blood-2004-10-4126. Epub 2005 Oct 13.
25	Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer. 2005 Sep 20;116(5):784-92. doi: 10.1002/ijc.21069.
26	Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor. J Urol. 2005 Aug;174(2):747-52. doi: 10.1097/01.ju.0000164723.20555.e6.
27	Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer. 2006 Sep;13(3):797-826. doi: 10.1677/erc.1.01143.
28	Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull. 2005 Jan;28(1):124-9.
29	Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells. Int J Cancer. 2006 Jan 1;118(1):90-7. doi: 10.1002/ijc.21297.
30	Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol. 2006 Feb;41(2):140-50.
31	Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
32	TCDD as a biological response modifier for Mitomycin C: oxygen tension affects enzyme activation, reactive oxygen species and cell death. Life Sci. 2006 Feb 23;78(13):1499-507. doi: 10.1016/j.lfs.2005.07.021. Epub 2005 Oct 14.
33	Expression of X-linked inhibitor of apoptosis protein and its effect on chemotherapeutic sensitivity of bladder carcinoma. J Huazhong Univ Sci Technolog Med Sci. 2007 Jun;27(3):285-7. doi: 10.1007/s11596-007-0317-5.
34	Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
35	Differences in sensitivity to DNA-damaging Agents between XRCC4- and Artemis-deficient human cells. J Radiat Res. 2011;52(4):415-24. doi: 10.1269/jrr.10168.
36	Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and ... Exp Toxicol Pathol. 2010 Sep;62(5):503-8.
37	In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate. J Gene Med. 2010 Jul;12(7):596-603.
38	Mitomycin C induces multidrug resistance in glaucoma surgery. Graefes Arch Clin Exp Ophthalmol. 2008 Feb;246(2):297-304. doi: 10.1007/s00417-007-0695-1. Epub 2007 Oct 13.
39	Genomic and proteomic profiling of responses to toxic metals in human lung cells. Environ Health Perspect. 2003 May;111(6):825-35.
40	Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac. World J Gastroenterol. 2005 Mar 28;11(12):1829-32.
41	Differential expression of TP53 associated genes in Fanconi anemia cells after mitomycin C and hydroxyurea treatment. Mutat Res. 2008 Oct 30;656(1-2):1-7.
42	Oxidative stress mechanisms do not discriminate between genotoxic and nongenotoxic liver carcinogens. Chem Res Toxicol. 2015 Aug 17;28(8):1636-46.
43	Trace levels of mitomycin C disrupt genomic integrity and lead to DNA damage response defect in long-term-cultured human embryonic stem cells. Arch Toxicol. 2015 Jan;89(1):33-45. doi: 10.1007/s00204-014-1250-6. Epub 2014 May 18.
44	Repairing of N-mustard derivative BO-1055 induced DNA damage requires NER, HR, and MGMT-dependent DNA repair mechanisms. Oncotarget. 2015 Sep 22;6(28):25770-83. doi: 10.18632/oncotarget.4514.
45	Effects of mitomycin-C on normal dermal fibroblasts. Laryngoscope. 2006 Apr;116(4):514-7. doi: 10.1097/01.MLG.0000205590.62824.0A.
46	Mitomycin induces alveolar epithelial cell senescence by down-regulating GSK3 signaling. Toxicol Lett. 2021 Nov 1;352:61-69. doi: 10.1016/j.toxlet.2021.09.015. Epub 2021 Oct 5.
47	DNA polymerase kappa protects human cells against MMC-induced genotoxicity through error-free translesion DNA synthesis. Genes Environ. 2017 Jan 7;39:6. doi: 10.1186/s41021-016-0067-3. eCollection 2017.
48	In vitro effect of cyclosporin A, mitomycin C and prednisolone on cell kinetics in cultured human umbilical vein endothelial cells. Thromb Res. 2005;115(3):219-28. doi: 10.1016/j.thromres.2004.09.001.
49	Chloramphenicol-induced mitochondrial stress increases p21 expression and prevents cell apoptosis through a p21-dependent pathway. J Biol Chem. 2005 Jul 15;280(28):26193-9. doi: 10.1074/jbc.M501371200. Epub 2005 May 19.
50	Dexamethasone reduces mitomycin C-related inflammatory cytokine expression without inducing further cell death in corneal fibroblasts. Wound Repair Regen. 2010 Jan-Feb;18(1):59-69. doi: 10.1111/j.1524-475X.2009.00551.x. Epub 2009 Dec 11.
51	The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939. Mol Biol Rep. 2010 Jul;37(6):2693-701. doi: 10.1007/s11033-009-9801-2. Epub 2009 Sep 13.
52	Comparison of the mutagenic potential of 17 physical and chemical agents analyzed by the flow cytometry mutation assay. Mutat Res. 2006 Dec 1;602(1-2):14-25. doi: 10.1016/j.mrfmmm.2006.07.009. Epub 2006 Oct 11.
53	Development of an integrated assay in human TK6 cells to permit comprehensive genotoxicity analysis in vitro. Mutat Res Genet Toxicol Environ Mutagen. 2020 Jan;849:503129. doi: 10.1016/j.mrgentox.2019.503129. Epub 2019 Dec 27.
54	Specific inhibition of rRNA transcription and dynamic relocation of fibrillarin induced by mercury. Exp Cell Res. 2000 Aug 25;259(1):225-38. doi: 10.1006/excr.2000.4923.
55	Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells. Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1071-7. doi: 10.1097/01.meg.0000231750.68513.6c.
56	Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells. Toxicol Appl Pharmacol. 2011 Sep 15;255(3):327-38. doi: 10.1016/j.taap.2011.07.012. Epub 2011 Jul 24.
57	Mitomycin-C induces the apoptosis of human Tenon's capsule fibroblast by activation of c-Jun N-terminal kinase 1 and caspase-3 protease. Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3545-52. doi: 10.1167/iovs.04-1358.
58	Mitomycin C induces apoptosis in a caspases-dependent and Fas/CD95-independent manner in human gastric adenocarcinoma cells. Cancer Lett. 2000 Oct 1;158(2):125-32. doi: 10.1016/s0304-3835(00)00489-4.
59	Mdm2 as a sensitive and mechanistically informative marker for genotoxicity induced by benzo[a]pyrene and dibenzo[a,l]pyrene. Toxicol Sci. 2008 Apr;102(2):232-40. doi: 10.1093/toxsci/kfm305. Epub 2007 Dec 20.
60	Mitomycin C induces apoptosis via Fas/FasL dependent pathway and suppression of IL-18 in cervical carcinoma cells. Cancer Lett. 2006 Jun 8;237(1):33-44. doi: 10.1016/j.canlet.2005.05.043. Epub 2005 Jul 12.
61	Mitomycin C induces apoptosis in cultured corneal fibroblasts derived from type II granular corneal dystrophy corneas. Mol Vis. 2008 Jun 30;14:1222-8.
62	FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair. Nat Genet. 2012 Jul 8;44(8):910-5. doi: 10.1038/ng.2347.
63	O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C. Toxicol Appl Pharmacol. 2006 Mar 1;211(2):97-105. doi: 10.1016/j.taap.2005.06.009. Epub 2005 Jul 22.
64	Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining. Oncotarget. 2015 Sep 29;6(29):27674-87. doi: 10.18632/oncotarget.4876.
65	MxA overexpression reveals a common genetic link in four Fanconi anemia complementation groups. J Clin Invest. 1997 Dec 1;100(11):2873-80. doi: 10.1172/JCI119836.
66	PP2A-B56? complex is involved in dephosphorylation of -H2AX in the repair process of CPT-induced DNA double-strand breaks. Toxicology. 2015 May 4;331:57-65. doi: 10.1016/j.tox.2015.03.007. Epub 2015 Mar 12.
67	Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells. J Biol Chem. 2005 Jul 29;280(30):27998-8006. doi: 10.1074/jbc.M503698200. Epub 2005 May 19.
68	Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res. 1995 Feb 1;55(3):590-6.
69	Methylation of Ras association domain family protein 1, isoform A correlated with proliferation and drug resistance in hepatocellular carcinoma cell line SMMC-7721. J Gastroenterol Hepatol. 2007 May;22(5):683-9. doi: 10.1111/j.1440-1746.2006.04676.x.
70	[Establishment of MRP-overexpression subline of bladder carcinoma and its MDR phenotype]. Zhonghua Zhong Liu Za Zhi. 2000 Jul;22(4):273-5.
71	Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1. Int J Cancer. 2005 Aug 10;116(1):155-60. doi: 10.1002/ijc.20919.
72	Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
73	[Effect of adenovirus-mediated mutant exogenous P27kip1 gene expression on the chemosensitivities of cholangiocarcinoma cell line]. Zhonghua Wai Ke Za Zhi. 2006 Oct 1;44(19):1349-52.
74	Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet. 2010 May;42(5):406-9. doi: 10.1038/ng.570. Epub 2010 Apr 18.
75	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
76	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.